

## TRACLEER® Prescription and Statement of Medical Necessity (PSMN)



Complete this form for ALL patients. Patients to complete and sign section 8 (pages 3 and 4) or submit a digital version of the Janssen Patient Support Program Patient Authorization at PAHconsent.com.



- Fax the following to 866-279-0669:

   This TRACLEER® Prescription and Medical Necessity form

   Prior Authorization (PA) form, signed and dated



For questions, please call the Bosentan REMS Program at 866-359-2612.

1 Patient Information (please print)						
(REQUIRED) First name		★(REQUIRED) L	ast name		★(REOUIRED) Birth date	_ Male Female  ★ (REQUIRED) Gend
(11401112)					(MM/DD/YYYY)	(iii (iii (iii )
(REQUIRED) Address		★(REQUIRED) C	ity		★(REQUIRED) State	★(REQUIRED) ZIP
nail address						English Spani
(REQUIRED) Primary phone #	Cell phone # orcheck if same as primary			Best time to call	Preferred Language	
egally authorized representative name		Relations	nip		Phone #	
Prescriber Information (please pri	nt)					
(REQUIRED) First name	*(REQL	JIRED) Last name	<u></u>	Specialty		
(REQUIRED) Site Name	*(PEOI	JIRED) Address				
(REQUIRED) Site Name	× (KEQI	dikeb) Address				
(REQUIRED) City				,	★ (REQUIRED) State	★ (REQUIRED) ZIP
Para analysis and a second	Office contact phone	#	Office contact email address		Fax#	
ice contact name						
(REQUIRED) Prescriber NPI		State license # certified pharmacy based on the	e patient's existing benefits.)	Prescribe	er Tax ID	
(REQUIRED) Prescriber NPI  rtified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Informa (REQUIRED) The following ICD-10 codes do not su	sent to the appropriate or ition (please pri ggest approval, cov	certified pharmacy based on the int) verage, or reimbursement	for specific uses or indications.	(Please chec	ck only one box below.)	
(REQUIRED) The following ICD-10 codes do not su  ICD-10 127.0 Primary pulmonary hypertension	sent to the appropriate of tion (please pringgest approval, cov	certified pharmacy based on the int) verage, or reimbursement 27.21 Secondary pulmonary	for specific uses or indications. arterial hypertension	(Please chec	ck only one box below.)	in to:
(REQUIRED) Prescriber NPI  artified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Information (REQUIRED) The following ICD-10 codes do not su  ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension	sent to the appropriate of tion (please pri ggest approval, cov	certified pharmacy based on the int)  verage, or reimbursement 27.21 Secondary pulmonary  tACLEER® (bosentan) Dosin and dispensing instructions: Co	for specific uses or indications. arterial hypertension [ g: 62.5 and 125 mg tablets implete A or 8 below	(Please chec	ck only one box below.)  * (REQUIRED) Sh  Patient home	
(REQUIRED) Prescriber NPI ertified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Informa (REQUIRED) The following ICD-10 codes do not su	sent to the appropriate of the sent to	certified pharmacy based on the int)  verage, or reimbursement  27.21 Secondary pulmonary	for specific uses or indications. arterial hypertension  [g: 62.5 and 125 mg tablets implete A or B below daily x 4 weeks, then increase	(Please chec	* (REQUIRED) Sh Patient home	ce
(REQUIRED) Prescriber NPI  ertified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Informa (REQUIRED) The following ICD-10 codes do not su  ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension  (REQUIRED) Pulmonary arterial hypertension  (AH) classification  Idiopathic PAH  Heritable PAH	sent to the appropriate of tion (please pri ggest approval, cov	certified pharmacy based on the int)  verage, or reimbursement  27.21 Secondary pulmonary  ACLEER® (bosentan) Dosin  and dispensing instructions: Co  e 62.5 mg tablet by mouth twice  he maintenance dose of 125 mg  ACLEER® 62.5 mg tablets (NDC 6	for specific uses or indications. arterial hypertension  [g: 62.5 and 125 mg tablets implete A or B below daily x 4 weeks, then increase	(Please chec	* (REQUIRED) Sh Patient home Prescriber offic Other—Please	ce
rtified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Informa (REQUIRED) The following ICD-10 codes do not su  ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension  AH) classification  Idiopathic PAH  Heritable PAH  Connective tissue disorder	sent to the appropriate of tion (please pri ggest approval, cov	certified pharmacy based on the int)  verage, or reimbursement  27.21 Secondary pulmonary  ACLEER® (bosentan) Dosin  and dispensing instructions: Co  e 62.5 mg tablet by mouth twice  he maintenance dose of 125 mg  ACLEER® 62.5 mg tablets (NDC 6	for specific uses or indications.  arterial hypertension  g: 62.5 and 125 mg tablets implete A or B below  d: daily x 4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills.	(Please chec	* (REQUIRED) Sh Patient home Prescriber offic Other—Please	ce e specify address if ent than patient home or
(REQUIRED) Prescriber NPI  sertified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Information (REQUIRED) The following ICD-10 codes do not sure ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension  (REQUIRED) Pulmonary arterial hypertension  (Hidiopathic PAH  Heritable PAH  Connective tissue disorder  Congenital heart disease	sent to the appropriate of tion (please pri ggest approval, cov	certified pharmacy based on the int)  verage, or reimbursement  27.21 Secondary pulmonary  ACLEER® (bosentan) Dosin  and dispensing instructions: Co  e 62.5 mg tablet by mouth twice  he maintenance dose of 125 mg  ACLEER® 62.5 mg tablets (NDC 6	for specific uses or indications. arterial hypertension  g: 62.5 and 125 mg tablets implete A or 8 below et daily x 4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills. 215-102-06) (60 tablets). Refill x 11.	(Please chec	* (REQUIRED) Sh Patient home Prescriber offic Other—Please	ce e specify address if ent than patient home or
rtified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Informa (REQUIRED) The following ICD-10 codes do not su  ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension  AH) classification  Idiopathic PAH  Heritable PAH  Connective tissue disorder	sent to the appropriate of the sent to the appropriate of the sent to the appropriate of the sent to t	certified pharmacy based on the int)  verage, or reimbursement  27.21 Secondary pulmonary  ACLEER® (bosentan) Dosin  and dispensing instructions: Co  e 62.5 mg tablet by mouth twice  he maintenance dose of 125 mg  ACLEER® 62.5 mg tablets (NDC 6	for specific uses or indications. arterial hypertension  g: 62.5 and 125 mg tablets implete A or B below didily x 4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills. 215-102-06) (60 tablets). Refill x 11.  OR	(Please chec	* (REQUIRED) Sh Patient home Prescriber offit Other—Please differe prescri	ce e specify address if ent than patient home or
(REQUIRED) Prescriber NPI  rtified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Informa (REQUIRED) The following ICD-10 codes do not su  ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension  AH) classification  Idiopathic PAH  Heritable PAH  Connective tissue disorder  Congenital heart disease	sent to the appropriate of the sent to the appropriate of the sent to the appropriate of the sent to t	certified pharmacy based on the int)  verage, or reimbursement  27.21 Secondary pulmonary  tACLEER® (bosentan) Dosin and dispensing instructions: Compared to the maintenance dose of 125 mg tablets (NDC 66)  CCLEER® 125 mg tablets (NDC 66)	for specific uses or indications. arterial hypertension  [g: 62.5 and 125 mg tablets implete A or 8 below daily x 4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills. 215-102-06) (60 tablets). Refill x 11.  OR	(Please chec	* (REQUIRED) Sh Patient home Prescriber offit Other—Please differe prescri	ce e specify address if ent than patient home or
(REQUIRED) Prescriber NPI  sertified pharmacy preference (If left blank, this referral will be  Prescription and Shipping Information (REQUIRED) The following ICD-10 codes do not sure ICD-10 127.0 Primary pulmonary hypertension  (REQUIRED) Pulmonary arterial hypertension  (REQUIRED) Pulmonary arterial hypertension  (Hidiopathic PAH  Heritable PAH  Connective tissue disorder  Congenital heart disease	sent to the appropriate of the sent to the appropriate of the sent to the appropriate of the sent to t	certified pharmacy based on the int.  verage, or reimbursement 27.21 Secondary pulmonary  tacLEER® (bosentan) Dosin and dispensing instructions: Co e 62.5 mg tablet by mouth twice he maintenance dose of 125 mg ACLEER® 62.5 mg tablets (NDC 66)  ACLEER® 125 mg tablets (NDC 66)  ACLEER® 125 mg tablets (NDC 66)  ACLEER® 125 mg tablets (NDC 66)	for specific uses or indications. arterial hypertension  g: 62.5 and 125 mg tablets implete A or 8 below daily x4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills. 215-102-06) (60 tablets). Refill x 11.  OR  (Qty) tablets Refill 115-102-06) (Qty) tablets Refill 115-102-06) (Qty) tablets Refill	(Please chec	* (REQUIRED) Sh Patient home Prescriber offit Other—Please differe prescri	ce e specify address if ent than patient home or
REQUIRED) Prescriber NPI  Trified pharmacy preference (if left blank, this referral will be referred will be	sent to the appropriate of the sent to the appropriate of the sent to the appropriate of the sent to t	certified pharmacy based on the int)  /erage, or reimbursement 27.21 Secondary pulmonary  tACLEER® (bosentan) Dosin and dispensing instructions: Co e 62.5 mg tablet by mouth twice he maintenance dose of 125 mg tablets (NDC 66 ACLEER® 125 mg tablets	for specific uses or indications. arterial hypertension  g: 62.5 and 125 mg tablets implete A or 8 below daily x4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills. 215-102-06) (60 tablets). Refill x 11.  OR  (Qty) tablets Refill 115-102-06) (Qty) tablets Refill 115-102-06) (Qty) tablets Refill	(Please chec	* (REQUIRED) Sh Patient home Prescriber offit Other—Please differe prescri	ce e specify address if ent than patient home or
REQUIRED) Prescriber NPI  Trified pharmacy preference (if left blank, this referral will be referred will be	sent to the appropriate of the sent to the appropriate of the sent to the appropriate of the sent to t	certified pharmacy based on the int)  /erage, or reimbursement 27.21 Secondary pulmonary  tACLEER® (bosentan) Dosin ind dispensing instructions: Color of the maintenance dose of 125 mg tablets (NDC 66)  ACLEER® 62.5 mg tablets (NDC 66)  ACLEER® 125 mg tablets (NDC 66)	for specific uses or indications. arterial hypertension  g: 62.5 and 125 mg tablets implete A or 8 below daily x4 weeks, then increase tablet by mouth twice daily. 6215-101-06) (60 tablets). No refills. 215-102-06) (60 tablets). Refill x 11.  OR  (Qty) tablets Refill 115-102-06) (Qty) tablets Refill 115-102-06) (Qty) tablets Refill	(Please chec	* (REQUIRED) Sh Patient home Prescriber office Other—Please differe prescri	ce e specify address if ent than patient home or

STAMPS). Prescriptions must be faxed.

Prescriber signature (dispense as written)

Date Date

Prescriber signature (substitution allowed)

The prescriber is to comply with their state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements

Please see the full Prescribing Information, including Boxed Warning about hepatotoxicity and embryo-fetal toxicity, and Medication Guide for TRACLEER® available at JanssenCarePath.com. Provide the Medication Guide to your patients and encourage discussion.





5 Diagnostic Testing (ple	ease print)				
Is the patient diagnosed with pulmonar pressure ≤ 15 mmHg, and pulmonary va			O, Group 1]), de	fined as mean pulmonary arterial pressure ≥ 25 mmH	lg, pulmonary arterial wedge
Is request submitted by, or under the re	commendation of, a puln	nonologist or cardiologist?	No		
Right heart catheterization (RHC)  Mean pulmonary artery pressure (mPAP)	mmHg	Acute vasoreactivity testing (CHECK ONE BOX)  Patient responded		Additional test results  WHO functional class	
Pulmonary arterial wedge pressure (PAWP)	mmHg	Patient did not respond		Echocardiography (See enclosed test results)	Date
Pulmonary vascular resistance (PVR)	Wood units	Date of test		6-minute walk distance (6MWD)	Date
				6-minute walk distance (6MWD)	Date
6 Current and Past Treat	ments (please prin	nt)			
Past treatment			Reason for disc	continuation	
Past treatment			Reason for disc	continuation	
Current treatment(s)			Current specia	lty pharmacies	
7 Insurance Information	(please print)				
Please provide copies of all medic	al and prescription in	surance cards (front and back).			
Insurance card and/or prescription c	ard attached				
Primary insurance			Subscriber nan	ne	
Name of insured			Policy#		
Group #		Phone #			
Secondary insurance			Subscriber nan	ne	
Name of insured			Policy#		
Group #			Phone #		

Please see the full Prescribing Information, including Boxed Warning about hepatotoxicity and embryo-fetal toxicity, and Medication Guide for TRACLEER® available at JanssenCarePath.com. Provide the Medication Guide to your patients and encourage discussion.

## 8 Janssen Patient Support Program Patient Authorization

Patients should (1) read the Patient Authorization, (2) check the desired permission boxes, and (3) return the form to Janssen Patient Support Program.

## Options to complete and return the form:

- A. Download a copy, print, check the desired boxes, and sign. The completed form may be faxed to 866-279-0669 or mailed to Janssen CarePath, PO Box 826, South San Francisco, CA 94083.
- B. Patients may also read, sign, and submit a digital version of this form at **PAHconsent.com**.

Patient name:	
Email address:	

I give permission for each of my "Healthcare Providers" (eg, my physicians, pharmacists, specialty pharmacies, other healthcare providers and their staff) and "Insurers" (eg, my health insurance plans) to share my Protected Health Information.

My "Protected Health Information" includes but is not limited to the following information related to my medical condition, treatment, prescriptions, and health insurance coverage.

The following person(s) or class of person(s) are given permission to receive and use my Protected Health Information (collectively "Janssen"):

- Johnson & Johnson Health Care Systems Inc., its affiliated companies, agents, and representatives
- Providers of other sources of funding include foundations and co-pay assistance providers
- Service providers supporting or analyzing data from Janssen patient support programs

Specifically, I give permission to Janssen to receive, use, and share my Protected Health Information in order to:

- see if I qualify for, sign me up for, and contact me about Janssen patient support programs
- manage the Janssen patient support programs
- give me educational and adherence materials, information, and resources related to my Janssen medication in connection with Janssen patient support programs
- communicate with my Healthcare Providers regarding access to, reimbursement for and fulfillment of my Janssen medication, and to confirm to my Healthcare Provider that support has been provided by the Janssen patient support programs
- verify, assist with, and coordinate my coverage for my Janssen medication with my Insurers and Healthcare Providers
- · coordinate prescription or treatment location and associated scheduling
- conduct analysis to help Janssen evaluate, create and improve its products, services, and customer support for patients prescribed Janssen medications
- share and give access to information created by the Janssen patient support programs that may be useful for my care

I understand that my Protected Health Information may be shared by Janssen for the uses written in this Form to:

- My Insurers
- My Healthcare Providers
- Any of the persons given permission to receive and use my Protected Health Information as mentioned above
- Any individual I give permission as an additional contact

## 8 Janssen Patient Support Program Patient Authorization (cont'd)

I understand that my Protected Health Information will not be used or shared by Janssen for any other use without my permission. Janssen may share information about me where legally allowed or if any information that specifically identifies me is removed. I understand that Janssen will make every effort to keep my information private. Further, I understand that if my information is accidentally shared, federal privacy laws do not require that the person/party receiving it not share the information further and that such information provided to a third party may no longer be protected by federal privacy laws. I understand that my pharmacy may receive compensation in connection with sharing my information with Janssen as allowed under this Authorization.

I understand that I am not required to sign this Form. My choice about whether to sign will not change how my Healthcare Providers or Insurers treat me. If I do not sign this Form, or cancel or remove my permission later, I understand I will not be able to participate or receive assistance from Janssen's patient support programs.

This Form will remain in effect 10 years from the date of signature, except where state law requires a shorter time, or until I am no longer participating in any Janssen patient support programs. Information collected before that date may continue to be used for the purposes set forth in this Form.

I understand that I may cancel the permissions given by this Form at any time by letting Janssen know in writing at: Janssen CarePath, PO Box 826, South San Francisco, CA 94083

I can also cancel my permission by letting my Healthcare Providers and Insurers know in writing that I do not want them to share any information with Janssen.

I further understand that if I cancel my permission it will not affect how Janssen uses and shares my Protected Health Information received by Janssen prior to my cancellation.

I understand I may request a copy of this Form.

Describe relationship to patient and authority to make medical decisions for pat	iont:
(Signature of person legally authorized to sign for patient)	
By: Print name:	Date:
If patient cannot sign, patient's legally authorized representative must sign below:	
Patient sign here:	Date:
Cell phone number:	
Permission for text communications:  Yes, I would like to receive text messages. By selecting this option, I agree to receive this form to the cell phone number provided below. Message and data rates may varies. I understand I am not required to provide my permission to receive text may Janssen patient support programs or to receive any other communications I have	y apply. Message frequency nessages to participate in the
at https://www.janssen.com/us/privacy-policy#california	Lailloi Illa privacy flotice avallable
For privacy rights and choices specific to California residents, please see Janssen's C	California privacy potico available
Yes, I would like to receive communications relating to other Janssen products a	and services.
Yes, I would like to receive communications relating to my Janssen medication.	
Permission for communications outside of Janssen patient support programs:	
randerstand rindy request a copy of this rollin.	

